Early test of malaria drug for deadly lung scarring disease
NCT ID NCT05988463
Summary
This is an early safety study to see if a drug called artesunate is safe and tolerable for people with Idiopathic Pulmonary Fibrosis (IPF), a serious disease that causes progressive lung scarring. About 15 participants will take the drug orally for 12 weeks at increasing doses to find the safest amount for future testing. The main goal is to check for side effects and see how the body handles the drug, while also looking for early signs it might help with lung function or symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University
RECRUITINGStanford, California, 94305, United States
Conditions
Explore the condition pages connected to this study.